Dana-Farber Cancer Institute and OncoHost partner for renal cell carcinoma research
Accounting for 4% of all cases, kidney cancer is currently the sixth most common cancer diagnosed in the UK
Read More
Tag: PROPHETIC
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
